Dr.
On
Mantle cell lymphoma (MCL) is a unique subtype of B-cell non-Hodgkin's lymphoma (NHL), which is invasive and incurable, with increasing incidence rate year by year1. MCL is usually in the late stage when diagnosed, facing the challenges of limited treatment and poor prognosis2.
About Orelabrutinib
Orelabrutinib is a highly selective BTK inhibitor developed by InnoCare for the treatment of cancers and autoimmune diseases.
On
The supplemental New Drug Applications of orelabrutinib for the treatment of R/R WM and R/R Marginal Zone Lymphoma were accepted in
In addition to the approved indications, multi-center, multi-indication clinical trials are underway in the US and
Orelabrutinib was granted as Breakthrough Therapy Designation for the treatment of r/r MCL by
In addition, orelabrutinib is also being evaluated in global phase II studies for the treatment of Multiple Sclerosis (MS), and clinical trials for the treatment of SLE, Primary Immune Thrombocytopenia (ITP) and Neuromyelitis Optica Spectrum Disorder (NMOSD) in
Forward-looking Statement
This report contains the disclosure of some forward-looking statements. Except for statements of facts, all other statements can be regarded as forward-looking statements, that is, about our or our management's intentions, plans, beliefs, or expectations that will or may occur in the future. Such statements are assumptions and estimates made by our management based on its experience and knowledge of historical trends, current conditions, expected future development and other related factors. This forward-looking statement does not guarantee future performance, and actual results, development and business decisions may not match the expectations of the forward-looking statement. Our forward-looking statements are also subject to a large number of risks and uncertainties, which may affect our short-term and long-term performance.
About InnoCare
InnoCare (HKEX: 09969; SSE: 688428) is a commercial stage biopharmaceutical company committed to discovering, developing, and commercializing first-in-class and/or best-in-class drugs for the treatment of cancer and autoimmune diseases. We strategically focus on liquid cancer, solid tumors, and autoimmune diseases with high unmet medical needs in
Contact:
Media
86-10-66609879
chunhua.lu@innocarepharma.com
Investors
86-10-66609999
ir@innocarepharma.com
(C) 2022 Electronic News Publishing, source